Tratamiento antiagregante en la isquemia cerebral: Ticlopidina frente aspirina

Revista de Neurologia

Volumn 24, Issue 126, 1996, Pages 214-218

  Rey, A ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Aspirin; Prevention; Stroke; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; ASPIRIN; BRAIN ISCHEMIA; CAROTID ARTERIES; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 0030076025     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Harker LA, Bruno JJ. Mecanisme de acción de la ticlopidina en las plaquetas humanas. En Hass WK, Easton JD, eds. Ticlopidina, plaquetas y patología vascular. Barcelona: Springer-Verlag Ibérica, 1994; 43-61.
2. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
3. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Ned 1989, 321: 501-507.
4. Warlow C. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for long-term use?. J Neurol Neurosurg Psychiatry 1990; 53: 185-187.
5. Murray JC, Kelly MA, Gorelick PB. Ticlopidine: a new antiplatelet agent for secondary prevention of stroke. Clin Neuropharmacol 1994; 17: 23-31.
6. Albers GW. Role of ticlopidine for prevention of stroke. Stroke 1992; 23: 912-916.
7. Grotta JC, Norris JW, Kamm B, et al. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992; 42: 111-115.
8. Wishnant JP. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-675.
9. Van Gijn J. Ticlopidines, trials and torture. Stroke 1994; 25: 1097-1098.
10. Easton JD. Papel de la ticlopidina en la prevención del ictus isquémico: valoración beneficio-riesgo. En Hass WK, Easton JD, eds. Ticlopidina, plaquetas y patología vascular. Barcelona: Springer-Verlag Ibérica, 1994; 157-163.
11. Sherman DG. Stroke prevention trials in atrial fibrillation. Cerebrovasc Dis 1992; 2 (Suppl 1): 14-17.
12. Koudstaal PJ. Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation. Eur Neurol 1993; 34: 61-63.
13. Flores-Runk P, Raasch R. Ticlopidine and antiplatelet therapy. Ann Pharmacother 1993; 27: 1090-1098.
14. Molony BA. Análisis de los efectos secundarios de la ticlopidina. En Hass WK, Easton JD, eds. Ticlopidina, plaquetas y patología vascular. Barcelona: Springer-Verlag Ibérica, 1994; 129-155.
15. UK-TIA study group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.